PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.16% | -17.43% | 2.10% | -8.80% | 0.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.94% | -16.59% | 1.00% | -11.37% | -6.63% |
| Operating Income | 8.94% | 16.59% | -1.00% | 11.37% | 6.63% |
| Income Before Tax | 1,866.55% | 552.43% | 107.73% | 79.70% | 77.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,866.55% | 552.43% | 107.73% | 79.70% | 77.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,866.55% | 552.43% | 107.73% | 79.70% | 77.32% |
| EBIT | 8.94% | 16.59% | -1.00% | 11.37% | 6.63% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 251.05% | 307.36% | -723.11% | -434.84% | -212.85% |
| Normalized Basic EPS | 4,575.65% | 307.69% | 285.34% | 95.06% | 106.83% |
| EPS Diluted | 198.80% | 242.66% | -724.24% | -435.72% | -210.74% |
| Normalized Diluted EPS | 4,575.65% | 307.69% | 285.34% | 95.06% | 106.83% |
| Average Basic Shares Outstanding | -44.19% | -52.01% | -51.00% | -41.65% | -31.21% |
| Average Diluted Shares Outstanding | -44.19% | -52.01% | -51.00% | -41.65% | -31.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
